Prevalence and severity of anaemia in persons with haemophilia and von Willebrand disease at Charlotte Maxeke Johannesburg Academic Hospital, South Africa
DOI:
https://doi.org/10.7196/SAMJ.2025.v116i3.3248Keywords:
Anaemia, Haemophilia, von willebrand diseaseAbstract
Background. Haemophilia and von Willebrand disease (VWD) are inherited bleeding diatheses characterised by spontaneous or traumatic bleeding resulting in varying degrees of anaemia. Early diagnosis, treatment and prevention of anaemia are crucial to improving physical and mental health and enhancing health-related quality of life. The global prevalence of anaemia and its associated risk factors is well established; however, there is a paucity of data on those with inherited bleeding disorders (IBD).
Objectives. To describe the prevalence and severity of anaemia in haemophilia and VWD in a quaternary care facility.
Methods. Adult patients with haemophilia or VWD of any subtype were identified through hospital record reviews. After excluding those without anaemia, defined as haemoglobin (HB) <13 g/dL for males and <12 g/dL for females, data from patients with anaemia were anonymised, captured, collated and analysed. Quantitative data were summarised with standard statistical tools, and qualitative data were described. The IBD cohort demographics, anaemia severity and prevalence data were compared with those of the controls, who were age- and sex-matched adult patients admitted to the haematology ward.
Results. Of 1 100 patients with IBD screened, 77 met the eligibility criteria. These comprised 68 (88.3%) haemophilia patients and 9 (11.7%) patients with VWD. The majority of IBD patients were males, comprising 90.9% (n=70), while females comprised 9.1% (n=7). Of the 886 screened controls, 77 age- and sex-matched patients were selected for comparison. The prevalence of anaemia in the study cohort was 38.96% (n=30). Most patients with anaemia (96.7%, n=29) were male, with only a single female, while in the control group, 85.7% (n=66) were male and 14.3% (n=11) were female. The prevalence of severe anaemia, defined as HB <8 g/dL, was 7% in the IBD group, compared with 22.8% in the control group. In the IBD group, 40% (n=12) of patients had borderline anaemia, compared with the control population with a predominance of life-threatening anaemia (31.2%, n=24). Mild anaemia (HB <11 g/dL) was noted in 37% of the IBD study cohort v. 13% in the control population. Life-threatening anaemia was seen in 13% of the IBD cohort v. 31.2% in the control population. The prevalence of moderate anaemia was 3% in the IBD cohort v. 28.6% in controls. In the IBD cohort, 43% of the anaemic patients had iron deficiency anaemia, and 6.5% of patients in the control group had iron deficiency anaemia.
Conclusion. This study indicates the burden of anaemia in the IBD population. Health professionals must be proactive in screening and treating anaemia in these patients. Further research is required to explore additional contributing factors. Optimisation of therapeutic strategies tailored to the unique needs of these patients is vital.
References
1. Prevalence, years lived with disability, and trends in anaemia burden by severity and cause, 1990 - 2021: Findings from the Global Burden of Disease Study 2021. Lancet Haematol 2023;10(9):e713-734.
2. World Health Organization. The global prevalence of anaemia in 2011. Geneva: WHO, 2011. https://www.who.int/ publications/i/item/9789241564960 (accessed 9 August 2024).
3. Camaschella C. Iron deficiency. Blood 2019;133(1):30-39.
https://doi.org/10.1182/blood.2022018610
4. Chaparro CM, Suchdev PS. Anemia epidemiology, pathophysiology, and etiology in low- and middle-income countries. Ann N Y Acad Sci 2019;1450(1):15-31. https://doi. org/10.1111/nyas.14092
5. AlliN,VaughanJ,LouwS,SchapkaitzE,MahlanguJ.Inherited bleeding disorders. S Afr Med J 2018;108(1):9-15. https://doi. org/10.7196/samj.2018.v108i1.13020
6. Rae C, Furlong W, Horsman J, et al. Bleeding disorders, menorrhagia and iron deficiency: Impacts on health-related quality of life. Haemophilia 2013;19(3):385-391. https://doi. org/10.1111/hae.12014
7. Lusher JM. Hemophilia: From plasma to recombinant factors. Hematology.org, 2008. https://www.hematology.org/about/ history/50-years/hemophilia (accessed 12 August 2024).
8. Coffin D, Gouider E, Konkie B, et al. The World Federation of Hemophilia World Bleeding Disorders Registry: Insights from the first 10,000 patients. Res Pract Thromb Haemost 2023;7(8):102264. https://doi.org/10.1016/j.rpth.2023.102264
9. Singh A, Rawat S, Kushwaha R, Jain M, Verma SP, Singh US. Clinicopathological parameters of haemophilia patients at a tertiary care centre in Northern India. Cureus 2023;15(7):e41670. https://doi.org/10.7759/cureuus.41670
10. Weyand AC, Flood VH. Von Willebrand disease: Current status of diagnosis and management. Hematol Oncol Clin North Am 2021;35(6):1085-1101. https://doi.org/10.1016/j. hoc.2021.07.004
11. James PD, Connell NT, Ameer B, et al. ASH ISTH NHF WFH 2021 guidelines on the diagnosis of von Willebrand disease. Blood Adv 2021;5(1):280-300. https://doi.org/10.1182/ bloodadvances.2020003265
12. Bharati KP, Prashanth UR. Von Willebrand disease: An overview. Indian J Pharm Sci 2011;73(1):7-16. https://doi. org/10.4103/0250-474x.89751
13. Gardner W, Razo C, McHugh T, et al. Prevalence, years lived with disability, and trends in anaemia burden by severity and cause, 1990 - 2021: Findings from the Global Burden of Disease Study 2021. Lancet Haematol 2023;10(9):e713-e734. https://doi.org/10.1016/s2352-3026(23)00160-6
14. Miller JL. Iron deficiency anemia: A common and curable disease. Cold Spring Harbor Perspect Med 2013;3(7): a011866. https://doi.org/10.1101/cshperspect.a011866
15. Dignass A, Farrag K, Stein J. Limitations of serum ferritin in diagnosing iron deficiency in inflammatory conditions. Int J Chronic Dis 2018;2018:9394060. https://doi. org/10.1155/2018/9394060
Downloads
Published
Issue
Section
License
Copyright (c) 2026 R Monaheng, J N Mahlangu
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Licensing Information
The SAMJ is published under an Attribution-Non Commercial International Creative Commons Attribution (CC-BY-NC 4.0) License. Under this license, authors agree to make articles available to users, without permission or fees, for any lawful, non-commercial purpose. Users may read, copy, or re-use published content as long as the author and original place of publication are properly cited.
Exceptions to this license model is allowed for UKRI and research funded by organisations requiring that research be published open-access without embargo, under a CC-BY licence. As per the journals archiving policy, authors are permitted to self-archive the author-accepted manuscript (AAM) in a repository.
Publishing Rights
Authors grant the Publisher the exclusive right to publish, display, reproduce and/or distribute the Work in print and electronic format and in any medium known or hereafter developed, including for commercial use. The Author also agrees that the Publisher may retain in print or electronic format more than one copy of the Work for the purpose of preservation, security and back-up.
